Fiber Laser Treatment Systems (HS-232,HS-233)

K251031 · Shanghai Apolo Medical Technology Co., Ltd. · ONG · Jul 2, 2025 · General, Plastic Surgery

Device Facts

Record IDK251031
Device NameFiber Laser Treatment Systems (HS-232,HS-233)
ApplicantShanghai Apolo Medical Technology Co., Ltd.
Product CodeONG · General, Plastic Surgery
Decision DateJul 2, 2025
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 878.4810
Device ClassClass 2
AttributesTherapeutic

Intended Use

1550nm: The Fiber Laser Treatment Systems is intended for use in dermatological procedures requiring fractional skin resurfacing and coagulation of soft tissue. 1927nm: The Fiber Laser Treatment Systems is intended for use in dermatological procedures requiring the coagulation of soft tissue.

Device Story

Fiber Laser Treatment Systems (HS-232 desktop, HS-233 mobile) utilize Erbium (1550nm) and Thulium (1927nm) fiber lasers for dermatological procedures. System components include mainframe with touchscreen, power supply, cooling system, fiber treatment handpiece, and footswitch. Operator selects laser source based on indication; 650nm aiming beam assists targeting. Footswitch activation delivers pulsed laser energy to treatment zone via optical fiber. Device used in clinical settings by trained professionals. Output provides fractional skin resurfacing or soft tissue coagulation; clinical decision-making guided by visual assessment of treatment area. Benefits include precise tissue interaction for dermatological applications.

Clinical Evidence

No clinical data. Substantial equivalence supported by non-clinical bench testing, including electrical safety (IEC 60601-1), electromagnetic compatibility (IEC 60601-1-2), and laser safety (IEC 60601-2-22, IEC 60825-1).

Technological Characteristics

Erbium (1550nm) and Thulium (1927nm) fiber laser; 650nm aiming beam (<2mW). Desktop (HS-232) or mobile (HS-233) form factor. Touchscreen interface. Patient-contact handpiece tips identical to K221770, compliant with ISO 10993-1. Standards: IEC 60601-1, IEC 60601-1-2, IEC 60601-2-22, IEC 60825-1.

Indications for Use

Indicated for dermatological procedures requiring fractional skin resurfacing and soft tissue coagulation using 1550nm or 1927nm laser wavelengths.

Regulatory Classification

Identification

(1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0} FDA U.S. FOOD &amp; DRUG ADMINISTRATION July 2, 2025 Shanghai Apolo Medical Technology Co., Ltd. Felix Li RA Supervisor Building 11, Lane 1566, Nanle Road, Songjiang District Shanghai, Shanghai 201613 China Re: K251031 Trade/Device Name: Fiber Laser Treatment Systems (HS-232, HS-233) Regulation Number: 21 CFR 878.4810 Regulation Name: Laser Surgical Instrument For Use In General And Plastic Surgery And In Dermatology Regulatory Class: Class II Product Code: ONG Dated: March 26, 2025 Received: April 3, 2025 Dear Felix Li: We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. U.S. Food &amp; Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 www.fda.gov {1} K251031 - Felix Li Page 2 Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download). Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181). Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050. All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems. For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory- {2} K251031 - Felix Li Page 3 assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely, TANISHA L. HITHE -S Digitally signed by TANISHA L. HITHE -S Date: 2025.07.02 13:59:56 -04'00' Tanisha Hithe Assistant Director DHT4A: Division of General Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health Enclosure {3} FORM FDA 3881 (6/20) Page 1 of 1 PSC Publishing Services (301) 443-6740 EF | DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Indications for Use | Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2023 See PRA Statement below. | | --- | --- | | 510(k) Number (if known) K251031 | | | Device Name Fiber Laser Treatment Systems (HS-232, HS-233) | | | Indications for Use (Describe) 1550nm: The Fiber Laser Treatment Systems is intended for use in dermatological procedures requiring fractional skin resurfacing and coagulation of soft tissue. 1927nm: The Fiber Laser Treatment Systems is intended for use in dermatological procedures requiring the coagulation of soft tissue. | | | Type of Use (Select one or both, as applicable) ☑ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C) | | | CONTINUE ON A SEPARATE PAGE IF NEEDED. | | | This section applies only to requirements of the Paperwork Reduction Act of 1995. *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* | | | The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." | | {4} | 510(k) #: K251031 | 510(k) Summary | Prepared on: 2025-05-30 | | --- | --- | --- | | Contact Details | | 21 CFR 807.92(a)(1) | | Applicant Name | Shanghai Apolo Medical Technology Co., Ltd. | | | Applicant Address | Building 11, Lane 1566, Nanle Road, Songjiang District Shanghai Shanghai 201613 China | | | Applicant Contact Telephone | +86-2134622015 | | | Applicant Contact | Mr. Felix Li | | | Applicant Contact Email | liqiang@apolo.com.cn | | | Device Name | | 21 CFR 807.92(a)(2) | | Device Trade Name | Fiber Laser Treatment Systems (HS-232,HS-233) | | | Common Name | Laser surgical instrument for use in general and plastic surgery and in dermatology | | | Classification Name | Powered Laser Surgical Instrument With MicrobeamFractional Output | | | Regulation Number | 878.4810 | | | Product Code(s) | ONG | | | Legally Marketed Predicate Devices | | 21 CFR 807.92(a)(3) | | Predicate # | Predicate Trade Name (Primary Predicate is listed first) | Product Code | | K221770 | Fiber Laser Treatment System | ONG | | K130193 | Fraxel® Dual 1550/1927 Laser System | GEX | | Device Description Summary | | 21 CFR 807.92(a)(4) | | The Fiber laser Treatment systems (HS-232) is the desktop type, and (HS-233) is the mobile type. It consists of mainframe(touch-screen data input system, power supply control system and cooling system), fiber treatment handpiece (laser output system) and footswitch. The Fiber Laser Treatment System is an Erbium(1550nm) and Thulium(1927nm) fiber laser, producing a pulsed beam upon activation by a footswitch. The system is equipped with a 650nm aiming beam with less than 2mW, the beam is then directed to treatment zone by mean of an optical fiber couple to a handpiece. The 1550nm laser and 1927nm laser works independently and cannot work together, the output laser source can be selected according to different indication for use | | | | Intended Use/Indications for Use | | 21 CFR 807.92(a)(5) | | 1550nm: The Fiber Laser Treatment Systems is intended for use in dermatological procedures requiring fractional skin resurfacing and coagulation of soft tissue. 1927nm: The Fiber Laser Treatment Systems is intended for use in dermatological procedures requiring the coagulation of soft tissue. | | | | Indications for Use Comparison | | 21 CFR 807.92(a)(5) | | The 1550nm indication of the proposed device is same as the predicate,the 1927nm indication of the proposed device is covered by the | | | {5} predicate. # Technological Comparison 21 CFR 807.92(a)(6) Discussion: 1550nm: - Indication for use: the indication for use of the proposed device is the same as the predicated device. - Technology: the proposed device utilizes the same technology as the predicates to achieve the intended use. The technical specifications including frequency, energy and pulse width are similar. Both devices meet the same standards of safety, EMC and performance requirements. - Material: The handpiece tip that contacts the patient are identical to that of the Fiber Laser Treatment System (K221770) manufactured by Shanghai Apolo, including the material, color, size, etc., so the contact part of the handpieces of the both devices comply with ISO 10993-1. 1927nm: Analysis 1: The indication for use of the proposed device is covered by the predicated devices. Analysis 2: From the above comparison, the output power of proposed device is 15W, the output power of predicate device is not exactly same, but the output power of proposed device is similar with higher value of output power of the predicate device, the minor difference does not the affect the indication of proposed device. The pulse energy is largely same as the predicate device, only the lowest energy is different, the lower pulse energy does not arise new safety issues. Analysis 3: The aiming beam and treatment area of the proposed device are similar with the predicate device's, the spot size and of the proposed device is within the range of the predicate device, so those minor difference does not affect the safety and effectiveness of device. Analysis 4: The 1550nm and 1927nm laser using the same handpiece with treatment tip to output the laser power. The handpiece tip that contacts the patient are identical to that of the Fiber Laser Treatment System (K221770) manufactured by Shanghai Apolo, including the material, color, size, etc. # Non-Clinical and/or Clinical Tests Summary &amp; Conclusions 21 CFR 807.92(b) Non-Clinical Testing: A battery of tests was performed to verify that the proposed device met all design specification. The test result demonstrated that the proposed device complies with the following standards: Electrical safety and electromagnetic compatibility IEC 60601-1: 2005+A1:2012+ A2:2020 Medical electrical equipment - Part 1: General requirements for basic safety and essential performance IEC 60601-1-2:2014+A1:2020 Medical electrical equipment -Part 1-2: General requirements for basic safety and essential performance- Collateral Standard: Electromagnetic disturbances - Requirements and tests IEC 60601-2-22:2019 Medical electrical equipment - Part 2-22: Particular requirements for the safety and essential performance of surgical, cosmetic, therapeutic and diagnostic laser equipment IEC 60825-1:2014 Safety of Laser products-Part 1: Equipment classification and requirements Clinical Testing: It is not applicable. Conclusions: Based on the performance testing and validation studies that the subject device is substantially equivalent to the predicate device.
Innolitics

Panel 1

/
Sort by
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from the tree

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...